Myth #1: Complying with Regulations and Product Specifications

A Scenario to Consider

You just closed out a US FDA inspection. A Form 483 was issued and it covered what appeared to be a manageable list of observations. For your response, you plan to gather further information to explain every sub-bullet example more effectively. You’ll list the changes you plan to make within your procedures to ensure the issues are not repeated. 

Let’s Take a Beat

Did you think to investigate the root causes of those failures (observations)? Was any time spent examining your operations and quality systems to see if there may be other related issues or similar problems elsewhere in your operation? These issues might play a bigger role than you imagine in impacting product quality and quality decision-making. 

Upon Closer Examination . . .

You encounter a media fill failure upon finding multiple turbid vials. After a detailed review of the manufacturing and laboratory data, you identify several potential root causes, addressing each and repeating the Aseptic Process Simulation.  

The repeat study ultimately meets specification requirements and commercial production is resumed. But, do you fully understand:

  • Types of contamination found?
  • Have you seen the substances before?
  • Where were the substances introduced into your operation?
  • How did the substances get there in the first place if your contamination control strategy and process controls were up to date?  

Did you adequately consider the potential impact on previous batches produced wherein the same materials, production process, equipment, and personnel were used? How did those batches pass if  less robust, routine release testing processes were employed? 

It’s a Trap!

At a certain level, the initial actions described in both scenarios read, fundamentally as fully compliant approaches. However, you may have just fallen into a faulty compliance trap versus a quality mindset  which is required to meet current industry and regulatory expectations. 

The challenge here is the mindset that comes with how we think of the term “compliance” versus expectation.  And where does quality fit in? All too often, being compliant is thought of as a means of achieving a requirement or standard. But how we apply that thought process is frequently far too narrowly applied in the immediate sense or scenario- intended to meet requirements or be compliant. 

While the GMPs established during the 1960s provide the requirements, I think we can all agree the expectations today have expanded since. Shifting was demanded in response to new technologies, new insights, and occasionally an unfortunate crisis we have all learned from. 

Learning and adapting is how we all remain vigilant against continuous and emerging threats that patients rely on us to control and avoid. If that’s the case, let’s offer a better focus.   

Quality is a continuous improvement mindset; it ensures product quality expectations are consistently met, ultimately ensuring sustained compliance. This mindset, where compliance is an outcome, is only achieved through consistent and fully extensive application of the aforementioned quality mindset and by a well-educated and fully capable organization with a mature quality culture. 

Avoid the compliance trap!


QxP COO Brian Duncan’s experience in pharma quality spans more than 20 years, including many years at Sandoz and Novartis prior to joining QxP.

The Crucial Nexus: Data Integrity in Pharmaceutical Manufacturing

Christine Feaster
May 17, 2024

Pharmaceutical Industry Trends for 2024 So Far

Christine Feaster
April 24, 2024

Decoding the Technical Transfer Process in Biotech Manufacturing

Sarah Boynton
April 23, 2024

Quality Executive Partners - IACET Accreditation

Ken Mead
April 9, 2024

Coaching and Correcting: A Focus on Behavior Over Blame

Sarah Boynton
November 1, 2023

The Importance of Roles and Responsibilities in Biotech Manufacturing & Human Error Prevention

Sarah Boynton
October 26, 2023

Remote cGMP Inspections and AI in Drug Manufacturing

Michelle Fishburne
October 11, 2023

4 Best Practices for Effective Investigation into Deviations

Sarah Boynton
September 19, 2023

The Art of Viral Vector Manufacturing: 4 Essential Controls to Prevent Cross-Contamination

Sarah Boynton
September 13, 2023

Practicing Risk Acceptance

Mark Roache
August 28, 2023

Annex 1 – Can we all take a deep breath now?

Vanessa Figueroa
August 24, 2023

In Cell and Gene, Good Science is Necessary, But Not Sufficient

Mark Roache
August 21, 2023

6 Ways To Achieve Manufacturing Audit And Inspection Readiness

Sarah Boynton
August 14, 2023

Experience is What You Get Just After You Needed It, Part 2

Mark Roache
August 10, 2023

Experience is What You Get Just After You Needed It, Part 1

Mark Roache
August 10, 2023

Sterility Assurance Matters to This ONE

Greg Gibb
August 8, 2023

Enhancing Quality and Safety: 3 Essential Human Error Prevention Tools for cGMP Manufacturing

Sarah Boynton
August 3, 2023

Asia-Pacific Happenings: Samsung Bioepis Implements QxP Virtuosi®

Michelle Fishburne
August 2, 2023

CDMOs – Selecting the Right One for Each Manufacturing Stage

Christine Feaster
July 24, 2023

3 Types of Human Error and Potential CAPAs to Prevent Them

Sarah Boynton
July 20, 2023

Drug Shortages: Causes & Solutions

Christine Feaster
July 10, 2023

The 5 Questions You Need to Ask After a Human Error Event Occurs

Sarah Boynton
July 5, 2023

Understanding How Adults Learn

Mike Levitt
June 30, 2023

Annex 1 and Ensuring Filling Technologies Fit the Need

Natasha Howard
June 21, 2023

How to Solve Pharma’s Skilled Workforce Deficit

Jeff Roy
June 20, 2023

ChatGPT Told Me AI is “Imperative” in Pharma Manufacturing

No items found.
June 18, 2023

Get Ready: FDORA’s Unannounced Foreign Inspection Pilot Program is On!

Crystal Mersh
June 6, 2023

Nitrosamines Impurity Challenges

Christine Feaster
June 2, 2023

All You Need to Know About Contamination Control Strategies, Parts 1 and 2

No items found.
June 1, 2023

When is ISO 8 Not ISO 8?

Bob Ferer
May 30, 2023

Cost Of Quality: Worth Every Cent In Bio/Pharmaceutical Manufacturing

Crystal Mersh
May 24, 2023

Pharmaceutical Quality is NOT a Spectator Sport

Mike Levitt
May 22, 2023

The Six Keys for Effective Deviation Investigators

Mike Levitt
May 18, 2023

There Has to be a Better Way to Train

Tyler DeWitt, Ph.D.
May 15, 2023

Cell and Gene: Article Series on CGT’s Key Drivers

Mark Roache
May 8, 2023

Bacterial Endotoxin Testing is on the Move

Christine Feaster
May 5, 2023

Top 20 Pharma Company Chooses QxP Virtuosi® Platform

Vanessa Figueroa
May 3, 2023

Crystal Clear: Controls Are Not Enough

Crystal Mersh
April 22, 2023

Myth #2: Proactively Remediating Bad Inspection Outcomes: What’s the benefit?

Brian Duncan
April 20, 2023

Is it Time to Outsource Internal Auditing?

Mike Levitt
April 18, 2023

Quality is Number One, Even When Trying to Address Supply Chain Issues

Christine Feaster
April 14, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 2

Bob Ferer
April 10, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 1

Bob Ferer
April 10, 2023